Laboratory research advancement in bevacizumab / 中华实验眼科杂志

ABSTRACT

Vascular endothelial growth factor (VEGF) is a key factor for neovascular diseases of ophthalmology.Bevacizumab is a full-length,humanized monoclonal IgG antibody,which prevents VEGF-A to combine with its receptors on the endothelial surface,and inhibits the endothelial cell proliferation and new blood vessel formation.Nowadays,anti-VEGF drugs are widely used to treat neovascularization diseases in ophthalmology.Bevacizumab has been more extensively applied because of its high security and low cost.The article reviewed the advancement of laboratory researches on the permeability,safety,pharmacokinetics of bevacizumab and research in vitro.